Semaglutide boosts walking ability in diabetes patients with peripheral artery disease, clinical trial finds

Published Date: 01 Apr 2025

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and type 2 diabetes in the first-of-its kind trial to evaluate ...

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

More Americans Are Surviving Cancer. But the Mental Health Challenges Can Persist.

2.

Glioma Outcomes Shaped by Subtype More Than Tx Sequence

3.

We Don't Always Know What's 'Best' for Our Patients

4.

Should the UK introduce targeted prostate cancer screening? The case for and against

5.

Germline Profiling May Improve Risk Stratification in t-MNs


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot